Poster

2019 AACR-NCI-EORTC (ANE) Molecular Targets: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor [...]

2019 SITC: Comprehensive and accurate prediction of presented neoantigens using ImmunoID NeXT and advanced machine learning algorithms Comprehensive detection of potential neoantigens and accurate prediction of their MHC presentation are critical prerequisites for selecting neoepitopes that can be used for creating personalized cancer vaccines. However, prediction models developed using in-vitro MHC-peptide purification followed by [...]

2019 SITC: T-cell receptor alpha and beta repertoire profiling using an augmented transcriptome The promise of immunotherapy has revealed the need for comprehensive profiling of the tumor and its immune microenvironment. This includes analysis of the T-cell receptor (TCR) repertoire, which has traditionally not been feasible with an exome/transcriptome platform. To address this challenge, [...]

2019 SITC: Comprehensive profiling of tumor-immune interaction in anti-PD-1 treated melanoma patients reveals subject-specific tumor escape mechanisms Checkpoint inhibitor therapy has demonstrated meaningful antitumor activity for many patients, though the majority fail to achieve complete response. Thus, it is of particular interest to identify biomarkers and mechanisms that promote positive response to immunotherapy. In [...]

2019 AACR: Applying immunopeptidomics and machine learning to improve neoantigen prediction for therapeutic and diagnostic use Neoantigens are increasingly critical in immuno-oncology as therapeutic targets for neoantigen-based personalized cancer vaccines (PCVs) and as potential biomarkers for immunotherapy response. However, optimizing technologies for identifying neoepitopes that are more likely to provoke an immune response remains [...]

2019 AACR: A comprehensive, highly accurate genomics platform for precision immunotherapy: Simultaneously characterize tumors and the TME from a single FFPE sample While the success of checkpoint blockade has been hugely promising, it’s increasingly apparent that predicting response to immunotherapies and developing new ones requires a more comprehensive approach to tumor immunogenomic profiling. We [...]

2019 AACR: T-cell receptor repertoire profiling using an augmented transcriptome Immunotherapy is growing as one of the most promising therapeutic approaches in clinical oncology practice. This brings with it an increasing need for comprehensive immuno-genomic profiling of tumors to better understand the interaction with the immune system. This includes profiling of the T and [...]

2019 AACR: Development and validation of an accurate exome-scale cfDNA detection platform Neoantigens are increasingly used as biomarkers for response to checkpoint blockade therapy and as therapeutic targets for neoantigen-based personalized cancer vaccines. Accurate identification of neoantigens requires comprehensive exome and transcriptome sequencing of both a tumor biopsy and a matched normal sample to [...]

2019 AACR: Sensitive detection of oncoviruses integrated into a comprehensive tumor immuno-genomics platformHPV, HBV, HCV and EBV viruses are causally linked to over 11% of cancers worldwide while KSHV, HTLV and MCV are linked to an additional 1%. As use of immunotherapy expands to a broader variety of cancers, it is important to understand how [...]

2018 SITC: More Sensitive Identification of T-cell Receptor Beta Arrangements with an Augmented Transcriptome Method With the increase in development and use of immunotherapies, there is also an increasing need for comprehensive immuno-genomic profiling of tumors to identify new potential biomarkers. This includes profiling of the T-cell receptor (TCR), which has traditionally not been [...]